EcoDrugPlus

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSACIG00000001293
Gene Symbol: PSMB4
1 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSACIG00000004798
Gene Symbol: PSMB5
1 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSACIG00000021396
Gene Symbol: PSMB6
1 Cross references
228 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSACIG00000014105
Gene Symbol: PSMB7
1 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSACIG00000018669
Gene Symbol: PSMB8A
1 Cross references
209 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSACIG00000006036
Gene Symbol: PSMB8A
2 Cross references
204 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSACIG00000020120
Gene Symbol: PSMB9A
1 Cross references
208 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSACIG00000019702
Gene Symbol: PSMB9A
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSACIG00000019740
Gene Symbol: PSMB9A
1 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSACIG00000021071
Gene Symbol: PSMD2
2 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSACIG00000003403
Gene Symbol: PSMD4A
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSACIG00000011041
Gene Symbol: PSMD4B
1 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).